Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | lipoxygenase | 0.0232 | 0.1214 | 0.1214 |
Toxoplasma gondii | MAPEG family protein | 0.1782 | 1 | 1 |
Echinococcus multilocularis | lipoxygenase domain containing protein | 0.0039 | 0.0122 | 0.0122 |
Brugia malayi | hypothetical protein | 0.0039 | 0.0122 | 0.19 |
Brugia malayi | Doublecortin family protein | 0.0039 | 0.0122 | 0.19 |
Onchocerca volvulus | 0.0039 | 0.0122 | 0.5 | |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0054 | 0.021 | 0.3287 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.013 | 0.064 | 1 |
Plasmodium vivax | multidomain scavenger receptor, putative | 0.0039 | 0.0122 | 1 |
Trypanosoma cruzi | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0017 | 0 | 0.5 |
Brugia malayi | hypothetical protein | 0.0039 | 0.0122 | 0.19 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0054 | 0.021 | 0.3287 |
Echinococcus granulosus | arachidonate 5 lipoxygenase | 0.0232 | 0.1214 | 0.1214 |
Echinococcus granulosus | lipoxygenase domain containing protein | 0.0039 | 0.0122 | 0.0122 |
Trypanosoma cruzi | isocitrate dehydrogenase, putative | 0.0017 | 0 | 0.5 |
Schistosoma mansoni | rab6-interacting | 0.0039 | 0.0122 | 0.0122 |
Plasmodium falciparum | LCCL domain-containing protein | 0.0039 | 0.0122 | 1 |
Echinococcus granulosus | lipoxygenase domain containing protein | 0.0039 | 0.0122 | 0.0122 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.013 | 0.064 | 1 |
Schistosoma mansoni | membrane associated proteins in eicosanoid and glutathione metabolism family member | 0.1782 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0054 | 0.021 | 0.3287 |
Schistosoma mansoni | microsomal glutathione s-transferase | 0.1782 | 1 | 1 |
Echinococcus multilocularis | Polycystic kidney disease protein | 0.0039 | 0.0122 | 0.0122 |
Loa Loa (eye worm) | doublecortin family protein | 0.0039 | 0.0122 | 0.19 |
Echinococcus granulosus | Polycystic kidney disease protein | 0.0039 | 0.0122 | 0.0122 |
Schistosoma mansoni | rab6-interacting | 0.0039 | 0.0122 | 0.0122 |
Echinococcus multilocularis | arachidonate 5 lipoxygenase | 0.0232 | 0.1214 | 0.1214 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0037 | 0.0113 | 0.1765 |
Brugia malayi | MH2 domain containing protein | 0.013 | 0.064 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0037 | 0.0113 | 0.0113 |
Mycobacterium tuberculosis | Probable isocitrate dehydrogenase [NADP] Icd1 (oxalosuccinate decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) | 0.0017 | 0 | 0.5 |
Echinococcus granulosus | RUN | 0.0039 | 0.0122 | 0.0122 |
Trypanosoma brucei | isocitrate dehydrogenase, putative | 0.0017 | 0 | 0.5 |
Schistosoma mansoni | loxhd1 | 0.0039 | 0.0122 | 0.0122 |
Trypanosoma brucei | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0017 | 0 | 0.5 |
Echinococcus multilocularis | RUN | 0.0039 | 0.0122 | 0.0122 |
Loa Loa (eye worm) | hypothetical protein | 0.0039 | 0.0122 | 0.19 |
Leishmania major | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0017 | 0 | 0.5 |
Onchocerca volvulus | 0.0039 | 0.0122 | 0.5 | |
Schistosoma mansoni | polycystin 1-related | 0.0039 | 0.0122 | 0.0122 |
Echinococcus multilocularis | lipoxygenase domain containing protein | 0.0039 | 0.0122 | 0.0122 |
Schistosoma mansoni | lipoxygenase | 0.0162 | 0.0819 | 0.0819 |
Loa Loa (eye worm) | hypothetical protein | 0.0039 | 0.0122 | 0.19 |
Loa Loa (eye worm) | hypothetical protein | 0.0037 | 0.0113 | 0.1765 |
Echinococcus multilocularis | microsomal glutathione S transferase 3 | 0.1782 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0039 | 0.0122 | 0.0122 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0054 | 0.021 | 0.3287 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.